Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 154Neoplasm Metastasis 10Prostatic Neoplasms, Castration-Resistant 8Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Breast Neoplasms 6Metastatic Castration Resistant Prostate Cancer 5Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Neoplasms, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Hormone Refractory Prostate Cancer × Abiraterone Acetate × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡